Search
UDP-alpha-D-glucuronic acid
go.drugbank.com/drugs/DB03041ExperimentalA nucleoside diphosphate sugar which serves as a source of glucuronic acid for polysaccharide biosynthesis. … In animals, UDP glucuronic acid is used for formation of many glucosiduronides with various aglycones. [PubChem]
Metolazone
go.drugbank.com/drugs/DB00524ApprovedInvestigationalA quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss.
Categories: Antihypertensive Agents Indicated for HypertensionEdivoxetine
go.drugbank.com/drugs/DB09184InvestigationalEdivoxetine failed to be approved for major depressive disorder after phase III clinical trials in 2012. … Edivoxetine is a drug which acts as a selective norepinephrine reuptake inhibitor and is currently under development by Eli Lilly for attention-deficit hyperactivity disorder (ADHD) and as an antidepressant
Garlic
go.drugbank.com/drugs/DB10532ApprovedNutraceuticalGarlic allergenic extract is used in allergenic testing.
Mixtures: BiO-LiFE Anti-FR+Selenium TabletsIrsogladine
go.drugbank.com/drugs/DB13056InvestigationalIrsogladine is under investigation in clinical trial NCT02581696 (The Drug-drug Interaction and Safety of Lafutidine and Irsogladine Maleate in Healthy Adult Volunteers).
Categories: Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)Fenfluramine
go.drugbank.com/drugs/DB00574ApprovedIllicitInvestigationalWithdrawn[A214688, A214691, A214700] Fenfluramine was granted initial FDA approval in 1973 prior to its withdrawal; it was granted a new FDA approval on June 25, 2020, for treatment of patients with Dravet syndrome
Rolapitant
go.drugbank.com/drugs/DB09291ApprovedInvestigationalRolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults.
Brentuximab
go.drugbank.com/drugs/DB05471InvestigationalSGN-30 received orphan drug designation from the FDA in July 2003 for Hodgkin lymphoma and in February 2004 for T-cell lymphomas. … SGN-30 has been shown to induce direct anti-cancer activity towards tumor cells expressing CD30 and is undergoing phase II trials for cancer therapy.
Carboprost tromethamine
go.drugbank.com/drugs/DB00429ApprovedInvestigationalA nonsteroidal abortifacient agent that is effective in both the first and second trimesters of pregnancy.